Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT05558982 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT05558982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05558982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Georgetown University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 16, 2023
Completion date
September 30, 2027
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic ductal adenocarcinoma